|
Bernardo RJ, Lu D, Ramirez RL 3rd, Hedlin H, Kawut SM, Bull T, De Marco T, Ford HJ, Grinnan D, Klinger JR, McConnell JW, Berman-Rosenzweig E, Shlobin OA, Zamanian RT, de Jesus Perez VA, PHAR Study Group.
"Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry." Annals of the American Thoracic Society, 2022.
|
|
Klinger JR, Matthay MA.
"Mesenchymal Stromal Cell Extracellular Vesicles: A New Approach for Preventing Bronchopulmonary Dysplasia?." Am J Respir Crit Care Med, vol. 205, no. 10, 2022, pp. 1138-1140.
|
|
LaPatra T, Baird GL, Goodman R, Pinder D, Gaffney M, Klinger JR, Palevsky HI, Fritz J, Mullin CJ, Mazurek JA, Kawut SM, Ventetuolo CE.
"Reply to: Remote 6-minute Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed?." Am J Respir Crit Care Med, vol. 206, no. 5, 2022, pp. 651-653.
|
|
Walsh TP, Baird GL, Atalay MK, Agarwal S, Arcuri D, Klinger JR, Mullin CJ, Morreo H, Normandin B, Shiva S, Whittenhall M, Ventetuolo CE.
"Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial." Pulmonary Circulation, vol. 11, no. 2, 2021, pp. 2045894021989554.
|
|
DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ.
"Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry." Pulmonary Circulation, vol. 11, no. 3, 2021, pp. 20458940211020913.
|
|
Baird GL, Walsh T, Aliotta J, Allahua M, Andrew R, Bourjeily G, Brodsky AS, Denver N, Dooner M, Harrington EO, Klinger JR, MacLean MR, Mullin CJ, Pereira M, Poppas A, Whittenhall M, Ventetuolo CE.
"Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension." Annals of the American Thoracic Society, vol. 18, no. 2, 2021, pp. 218-228.
|
|
Klinger JR.
"Novel Pharmacological Targets for Pulmonary Arterial Hypertension." Comprehensive Physiology, vol. 11, no. 4, 2021, pp. 2297-2349.
|
|
Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, Shlobin O, Simon M, Thenappan T, Grinnan D, Ventetuolo C, Al-Naamani N, PHAR Investigators.
"Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry." Am J Respir Crit Care Med, vol. 203, no. 6, 2021, pp. 761-764.
|
|
Klinger JR, Chakinala MM, Langleben D, Rosenkranz S, Sitbon O.
"Riociguat: Clinical research and evolving role in therapy." British journal of clinical pharmacology, vol. 87, no. 7, 2021, pp. 2645-2662.
|
|
Banerjee D, Grammatopoulos TN, Palmisciano A, Klinger JR, Krishnan I, Whittenhall M, Zhou A, Dudley S, Ventetuolo CE.
"Alternative Splicing of the Cardiac Sodium Channel in Pulmonary Arterial Hypertension." Chest, vol. 158, no. 2, 2020, pp. 735-738.
|
|
Vazquez ZGS, Klinger JR.
"Guidelines for the Treatment of Pulmonary Arterial Hypertension." Lung, vol. 198, no. 4, 2020, pp. 581-596.
|
|
Klinger JR, Pereira M, Del Tatto M, Brodsky AS, Wu KQ, Dooner MS, Borgovan T, Wen S, Goldberg LR, Aliotta JM, Ventetuolo CE, Quesenberry PJ, Liang OD.
"Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats." American Journal of Respiratory Cell and Molecular Biology, vol. 62, no. 5, 2020, pp. 577-587.
|
|
Huluka DK, Mekonnen D, Abebe S, Meshesha A, Mekonnen D, Deyessa N, Klinger JR, Ventetuolo CE, Schluger NW, Sherman CB, Amogne W.
"Prevalence and risk factors of pulmonary hypertension among adult patients with HIV infection in Ethiopia." Pulmonary Circulation, vol. 10, no. 4, 2020, pp. 2045894020971518.
|
|
Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, Maloney J, De Marco T, Ivy D, Thenappan T, Sager JS, Ryan JJ, Mazimba S, Hirsch R, Chakinala M, Shlobin O, Lammi M, Zwicke D, Robinson J, Benza RL, Klinger J, Grinnan D, Mathai S, Badesch D.
"Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry." Pulmonary Circulation, vol. 10, no. 4, 2020, pp. 2045894020964342.
|
|
Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR, UK NIHR BioResource Rare Diseases Consortium., UK PAH Cohort Study Consortium., US PAH Biobank Consortium.
"Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis." The Lancet Respiratory Medicine, vol. 7, no. 3, 2019, pp. 227-238.
|
|
Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M.
"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives." European Respiratory Journal, vol. 53, no. 1, 2019.
|
|
Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB.
"Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report." Chest, vol. 155, no. 3, 2019, pp. 565-586.
|
|
Mullin CJ, Klinger JR.
"Chronic Thromboembolic Pulmonary Hypertension." Heart Failure Clinics, vol. 14, no. 3, 2018, pp. 339-351.
|
|
Baird GL, Archer-Chicko C, Barr RG, Bluemke DA, Foderaro AE, Fritz JS, Hill NS, Kawut SM, Klinger JR, Lima JAC, Mullin CJ, Ouyang P, Palevsky HI, Palmisicano AJ, Pinder D, Preston IR, Roberts KE, Smith KA, Walsh T, Whittenhall M, Ventetuolo CE.
"Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension." European Respiratory Journal, vol. 51, no. 6, 2018.
|
|
Kawut SM, Archer-Chicko CL, DiMichele A, Fritz JS, Klinger JR, Ky B, Palevsky HI, Palmisciano AJ, Patel M, Pinder D, Propert KJ, Smith KA, Stanczyk F, Tracy R, Vaidya A, Whittenhall ME, Ventetuolo CE.
"Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial." Am J Respir Crit Care Med, vol. 195, no. 3, 2017, pp. 360-368.
|
|
Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, Cheng Y, Goldberg L, Ventetuolo CE, Liang O, Klinger JR, Quesenberry PJ.
"Bone Marrow Endothelial Progenitor Cells Are the Cellular Mediators of Pulmonary Hypertension in the Murine Monocrotaline Injury Model." STEM CELLS Translational Medicine, vol. 6, no. 7, 2017, pp. 1595-1606.
|
|
Stewart LK, Nordenholz KE, Courtney M, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Kline JA.
"Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo." Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, vol. 28, no. 8, 2017, pp. 675-680.
|
|
Foderaro AE, Baird GL, Bazargan-Lari A, Morrissey PE, Gohh RY, Poppas A, Klinger JR, Ventetuolo CE.
"Echocardiographic Pulmonary Hypertension Predicts Post-transplantation Renal Allograft Failure." Transplantation Proceedings, vol. 49, no. 6, 2017, pp. 1256-1261.
|
|
Liang OD, So EY, Egan PC, Goldberg LR, Aliotta JM, Wu KQ, Dubielecka PM, Ventetuolo CE, Reginato AM, Quesenberry PJ, Klinger JR.
"Endothelial to haematopoietic transition contributes to pulmonary arterial hypertension." Cardiovascular research, vol. 113, no. 13, 2017, pp. 1560-1573.
|
|
Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA.
"Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors." Respiratory Medicine, vol. 122 Suppl 1, 2017, pp. S18-S22.
|
|
Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.
"RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors." European Respiratory Journal, vol. 50, no. 3, 2017.
|
|
Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR.
"Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension." Chest, vol. 151, no. 2, 2017, pp. 468-480.
|
|
Ventetuolo CE, Hess E, Austin ED, Barón AE, Klinger JR, Lahm T, Maddox TM, Plomondon ME, Thompson L, Zamanian RT, Choudhary G, Maron BA.
"Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database." PLoS ONE, vol. 12, no. 11, 2017, pp. e0187734.
|
|
Banerjee D, Kamuren J, Baird GL, Palmisciano A, Krishnan I, Whittenhall M, Klinger JR, Ventetuolo CE.
"The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension." Pulmonary Circulation, vol. 7, no. 2, 2017, pp. 384-390.
|
|
Klinger JR, Kadowitz PJ.
"The Nitric Oxide Pathway in Pulmonary Vascular Disease." The American Journal of Cardiology, vol. 120, no. 8S, 2017, pp. S71-S79.
|
|
Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, Goldberg LR, Baird GL, Ventetuolo CE, Quesenberry PJ, Klinger JR.
"Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice." Cardiovascular research, vol. 110, no. 3, 2016, pp. 319-30.
|
|
Klinger JR.
"Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments." Cardiology clinics, vol. 34, no. 3, 2016, pp. 413-33.
|
|
Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Lima JA, Ouyang P, Palevsky HI, Palmisciano AJ, Krishnan I, Pinder D, Preston IR, Roberts KE, Kawut SM.
"Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated With Pulmonary Arterial Hypertension in Men." Am J Respir Crit Care Med, vol. 193, no. 10, 2016, pp. 1168-75.
|
|
Klinger JR.
"Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?." European Respiratory Journal, vol. 48, no. 5, 2016, pp. 1265-1267.
|
|
Talwar A, Sahni S, Talwar A, Kohn N, Klinger JR.
"Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation." Pulmonary Circulation, vol. 6, no. 2, 2016, pp. 191-5.
|
|
Klinger, James, McMahon, Timothy, Dweik, Raed, Platt, David, O'Brien, Gerald, Satler, Carol.
"Toward More Individualized Treatment of Pulmonary Arterial Hypertension: Investigation of Biomarkers for Nitric Oxide Deficiency." Chest, vol. 148, no. 4_MeetingAbstracts, 2015, pp. 953A.
|
|
Ventetuolo CE, Gabler NB, Fritz JS, Smith KA, Palevsky HI, Klinger JR, Halpern SD, Kawut SM.
"Are hemodynamics surrogate end points in pulmonary arterial hypertension?." Circulation, vol. 130, no. 9, 2014, pp. 768-75.
|
|
Stewart, Lauren K., Peitz, Geoffrey W., Nordenholz, Kristen E., Courtney, D. Mark, Kabrhel, Christopher, Jones, Alan E., Rondina, Matthew T., Diercks, Deborah B., Klinger, James R., Kline, Jeffrey A.
"Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism." J Thromb Thrombolysis, vol. 40, no. 2, 2014, pp. 161-166.
|
|
Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D, Canadian Critical Care Trials Group., Australia and New Zealand Intensive Care Society Clinical Trials Group.
"Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients." JAMA, vol. 312, no. 20, 2014, pp. 2135-45.
|
|
Fowler RA, Mittmann N, Geerts WH, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D, Canadian Critical Care Trials Group, Australia and New Zealand Intensive Care Society Clinical Trials Group.
"Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial." Trials, vol. 15, 2014, pp. 502.
|
|
Berman-Rosenzweig E, Arneson C, Klinger JR.
"Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension." Pulmonary Circulation, vol. 4, no. 1, 2014, pp. 45-52.
|
|
Crowther M, Cook D, Guyatt G, Zytaruk N, McDonald E, Williamson D, Albert M, Dodek P, Finfer S, Vallance S, Heels-Ansdell D, McIntyre L, Mehta S, Lamontagne F, Muscedere J, Jacka M, Lesur O, Kutsiogiannis J, Friedrich J, Klinger JR, Qushmaq I, Burry L, Khwaja K, Sheppard JA, Warkentin TE, PROTECT collaborators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group.
"Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial." Journal of Critical Care, vol. 29, no. 3, 2014, pp. 470.e7-15.
|
|
Ventetuolo CE, Klinger JR.
"Management of acute right ventricular failure in the intensive care unit." Annals of the American Thoracic Society, vol. 11, no. 5, 2014, pp. 811-22.
|
|
Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB.
"Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults: CHEST Guideline and Expert Panel Report." Chest, vol. 146, no. 2, 2014, pp. 449-75.
|
|
Katsios C, Donadini M, Meade M, Mehta S, Hall R, Granton J, Kutsogiannis J, Dodek P, Heels-Ansdell D, McIntyre L, Vlahakis N, Muscedere J, Friedrich J, Fowler R, Skrobik Y, Albert M, Cox M, Klinger J, Nates J, Bersten A, Doig C, Zytaruk N, Crowther M, Cook DJ.
"Prediction scores do not correlate with clinically adjudicated categories of pulmonary embolism in critically ill patients." Canadian respiratory journal : journal of the Canadian Thoracic Society, vol. 21, no. 1, 2014, pp. 36-42.
|
|
Sangal RB, Taylor LE, Gillani F, Poppas A, Klinger JR, Ventetuolo CE.
"Risk of Echocardiographic Pulmonary Hypertension in Individuals with Human Immunodeficiency Virus–Hepatitis C Virus Coinfection." Annals ATS, vol. 11, no. 10, 2014, pp. 1553-9.
|
|
Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM.
"Sex and haemodynamics in pulmonary arterial hypertension." European Respiratory Journal, vol. 43, no. 2, 2014, pp. 523-30.
|
|
Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J.
"Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial." Journal of thrombosis and haemostasis : JTH, vol. 12, no. 4, 2014, pp. 459-68.
|
|
Klinger JR, Tsai SW, Green S, Grinnell KL, Machan JT, Harrington EO.
"Atrial natriuretic peptide attenuates agonist-induced pulmonary edema in mice with targeted disruption of the gene for natriuretic peptide receptor-A." Journal of Applied Physiology, vol. 114, no. 3, 2013, pp. 307-15.
|
|
Aliotta JM, Pereira M, Amaral A, Sorokina A, Igbinoba Z, Hasslinger A, El-Bizri R, Rounds SI, Quesenberry PJ, Klinger JR.
"Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice." Cardiovascular research, vol. 100, no. 3, 2013, pp. 354-62.
|
|
Klinger JR, Abman SH, Gladwin MT.
"Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension." Am J Respir Crit Care Med, vol. 188, no. 6, 2013, pp. 639-46.
|
|
Channick R, Preston I, Klinger JR.
"Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors." Clinics in Chest Medicine, vol. 34, no. 4, 2013, pp. 811-24.
|
|
Kline JA, Hernandez J, Hogg MM, Jones AE, Courtney DM, Kabrhel C, Nordenholz KE, Diercks DB, Rondina MT, Klinger JR.
"Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes." Emergency medicine Australasia : EMA, vol. 25, no. 6, 2013, pp. 515-26.
|
|
Chichger H, Grinnell KL, Casserly B, Chung CS, Braza J, Lomas-Neira J, Ayala A, Rounds S, Klinger JR, Harrington EO.
"Genetic disruption of protein kinase Cδ reduces endotoxin-induced lung injury." American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 303, no. 10, 2012, pp. L880-8.
|
|
Gartman EJ, Blundin M, Klinger JR, Yammine J, Roberts MB, Dennis McCool F.
"Initial risk assessment for pulmonary hypertension in patients with COPD." Lung, vol. 190, no. 1, 2012, pp. 83-9.
|
|
Sears EH, Aliotta JM, Klinger JR.
"Partial anomalous pulmonary venous return presenting with adult-onset pulmonary hypertension." Pulmonary Circulation, vol. 2, no. 2, 2012, pp. 250-5.
|
|
Lutz K, Wilton K, Zytaruk N, Julien L, Hall R, Harvey J, Skrobik Y, Vlahakis N, Meade L, Matte A, Meade M, Burns K, Albert M, Cash BB, Vallance S, Klinger J, Heels-Ansdell D, Cook D, PROTECT Investigators in collaboration with the CCCTG and ANZICS-CTG.
"Research ethics board approval for an international thromboprophylaxis trial." Journal of Critical Care, vol. 27, no. 3, 2012, pp. 225-31.
|
|
Peters-Golden M, Klinger JR, Carson SS, ATS Research Advocacy Committee.
"The case for increased funding for research in pulmonary and critical care." Am J Respir Crit Care Med, vol. 186, no. 3, 2012, pp. 213-5.
|
|
Ventetuolo CE, Klinger JR.
"WHO Group 1 pulmonary arterial hypertension: current and investigative therapies." Progress in Cardiovascular Diseases, vol. 55, no. 2, 2012, pp. 89-103.
|
|
Choudhary G, Troncales F, Martin D, Harrington EO, Klinger JR.
"Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension." The Journal of Heart and Lung Transplantation, vol. 30, no. 7, 2011, pp. 827-33.
|
|
Casserly B, Mazer JM, Vang A, Harrington EO, Klinger JR, Rounds S, Choudhary G.
"C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade." Life sciences, vol. 89, no. 13-14, 2011, pp. 460-6.
|
|
Levinson AT, Klinger JR.
"Combination therapy for the treatment of pulmonary arterial hypertension." Therapeutic advances in respiratory disease, vol. 5, no. 6, 2011, pp. 419-30.
|
|
Houtchens J, Martin D, Klinger JR.
"Diagnosis and management of pulmonary arterial hypertension." Pulmonary Medicine, vol. 2011, 2011, pp. 845864.
|
|
Stone AC, Machan JT, Mazer J, Casserly B, Klinger JR.
"Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease." Lung, vol. 189, no. 3, 2011, pp. 207-12.
|
|
Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.
"Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension." The American Journal of Cardiology, vol. 108, no. 2, 2011, pp. 302-7.
|
|
Fayngersh V, Drakopanagiotakis F, Dennis McCool F, Klinger JR.
"Pulmonary hypertension in a stable community-based COPD population." Lung, vol. 189, no. 5, 2011, pp. 377-82.
|
|
Casserly B, Atalay MK, Poppas A, Klinger JR, Abu-Hijleh M.
"Pulmonary puzzle. An unusual cause of chest pain. Diagnosis: Cor triatriatum sinistrum with secondary unilateral pulmonary venous hypertension and right lung hypoplasia." Thorax, vol. 66, no. 4, 2011, pp. 285-6, 313-4.
|
|
Klinger JR.
"Tadalafil for the treatment of pulmonary arterial hypertension." Expert review of respiratory medicine, vol. 5, no. 3, 2011, pp. 315-28.
|
|
Casserly B, Pietras L, Schuyler J, Wang R, Hill NS, Klinger JR.
"Cardiac atria are the primary source of ANP release in hypoxia-adapted rats." Life sciences, vol. 87, no. 11-12, 2010, pp. 382-9.
|
|
Mehta S, Heffer MJ, Maham N, Nelson DL, Klinger JR, Levy MM.
"Impact of endotracheal tube size on preextubation respiratory variables." Journal of Critical Care, vol. 25, no. 3, 2010, pp. 483-8.
|
|
Casserly B, Klinger JR.
"Ambrisentan for the treatment of pulmonary arterial hypertension." Drug design, development and therapy, vol. 2, 2009, pp. 265-80.
|
|
Casserly B, Klinger JR.
"Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent." Drug design, development and therapy, vol. 3, 2009, pp. 269-87.
|
|
Aliotta JM, Keaney PJ, Warburton RR, DelTatto M, Dooner MS, Passero MA, Quesenberry PJ, Klinger JR.
"Marrow cell infusion attenuates vascular remodeling in a murine model of monocrotaline-induced pulmonary hypertension." Stem Cells and Development, vol. 18, no. 5, 2009, pp. 773-82.
|
|
Chan CM, Klinger JR.
"The right ventricle in sepsis." Clinics in Chest Medicine, vol. 29, no. 4, 2008, pp. 661-76, ix.
|
|
Klinger JR.
"Pulmonary arterial hypertension: an overview." Seminars in cardiothoracic and vascular anesthesia, vol. 11, no. 2, 2007, pp. 96-103.
|
|
Hill NS, Klinger JR.
"Pulmonary hypertension in the intensive care unit: Critical role of the right ventricle." Critical care medicine, vol. 35, no. 9, 2007, pp. 2210-1.
|
|
Klinger JR, Murray JD, Casserly B, Alvarez DF, King JA, An SS, Choudhary G, Owusu-Sarfo AN, Warburton R, Harrington EO.
"Rottlerin causes pulmonary edema in vivo: a possible role for PKCdelta." Journal of Applied Physiology, vol. 103, no. 6, 2007, pp. 2084-94.
|
|
Klinger JR.
"The nitric oxide/cGMP signaling pathway in pulmonary hypertension." Clinics in Chest Medicine, vol. 28, no. 1, 2007, pp. 143-67, ix.
|
|
Steiner MK, Preston IR, Klinger JR, Criner GJ, Waxman AB, Farber HW, Hill NS.
"Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study." Chest, vol. 130, no. 5, 2006, pp. 1471-80.
|
|
Klinger JR, Warburton R, Carino GP, Murray J, Murphy C, Napier M, Harrington EO.
"Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells." Experimental Cell Research, vol. 312, no. 4, 2006, pp. 401-10.
|
|
Martin KB, Klinger JR, Rounds SI.
"Pulmonary arterial hypertension: new insights and new hope." Respirology (Carlton, Vic.), vol. 11, no. 1, 2006, pp. 6-17.
|
|
Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW.
"Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension." Chest, vol. 129, no. 2, 2006, pp. 417-25.
|
|
Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS.
"Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension." Respiratory Medicine, vol. 99, no. 12, 2005, pp. 1501-10.
|
|
Klinger JR, Houtchens J, Thaker S, Hill NS, Farber H.
"Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension." Chest, vol. 128, no. 6 Suppl, 2005, pp. 618S-619S.
|
|
Steiner MK, Preston IR, Klinger JR, Hill NS.
"Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides." Current opinion in pharmacology, vol. 5, no. 3, 2005, pp. 245-50.
|
|
Aliotta JM, Passero M, Meharg J, Klinger J, Dooner MS, Pimentel J, Quesenberry PJ.
"Stem cells and pulmonary metamorphosis: new concepts in repair and regeneration." Journal of cellular physiology, vol. 204, no. 3, 2005, pp. 725-41.
|
|
Preston IR, Hill NS, Gambardella LS, Warburton RR, Klinger JR.
"Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension." Experimental Biology and Medicine, vol. 229, no. 9, 2004, pp. 920-5.
|
|
Karamsetty MR, Klinger JR, Hill NS.
"Evidence for the role of p38 MAP kinase in hypoxia-induced pulmonary vasoconstriction." American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 283, no. 4, 2002, pp. L859-66.
|
|
Klinger JR.
"Inhaled nitric oxide in ARDS." Critical Care Clinics, vol. 18, no. 1, 2002, pp. 45-68, vi.
|
|
Karamsetty MR, Klinger JR.
"NO: more than just a vasodilator in lung transplantation." American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 1, 2002, pp. 1-5.
|
|
Preston IR, Klinger JR, Houtchens J, Nelson D, Mehta S, Hill NS.
"Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome." Chest, vol. 121, no. 2, 2002, pp. 656-9.
|
|
Ward NS, Lin DY, Nelson DL, Houtchens J, Schwartz WA, Klinger JR, Hill NS, Levy MM.
"Successful determination of lower inflection point and maximal compliance in a population of patients with acute respiratory distress syndrome." Critical care medicine, vol. 30, no. 5, 2002, pp. 963-8.
|
|
Klinger JR, Warburton RR, Pietras L, Oliver P, Fox J, Smithies O, Hill NS.
"Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy." AJP: Heart and Circulatory Physiology, vol. 282, no. 1, 2002, pp. H58-65.
|
|
Karamsetty MR, Nakashima JM, Ou L, Klinger JR, Hill NS.
"EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats." American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 280, no. 3, 2001, pp. L458-64.
|
|
Karamsetty MR, Klinger JR, Hill NS.
"Phytoestrogens restore nitric oxide-mediated relaxation in isolated pulmonary arteries from chronically hypoxic rats." The Journal of pharmacology and experimental therapeutics, vol. 297, no. 3, 2001, pp. 968-74.
|
|
Klinger JR, Pietras L, Warburton R, Hill NS.
"Reduced oxygen tension increases atrial natriuretic peptide release from atrial cardiocytes." Experimental Biology and Medicine, vol. 226, no. 9, 2001, pp. 847-53.
|
|
Karamsetty MR, Pietras L, Klinger JR, Lanzillo JJ, Leiter JC, Ou LC, Hill NS.
"The role of endothelin-1 in strain-related susceptibility to develop hypoxic pulmonary hypertension in rats." Respiration physiology, vol. 128, no. 2, 2001, pp. 219-27.
|
|
Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS.
"Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension." Chest, vol. 120, no. 3, 2001, pp. 866-72.
|
|
Mehta S, Nelson DL, Klinger JR, Buczko GB, Levy MM.
"Prediction of post-extubation work of breathing." Critical care medicine, vol. 28, no. 5, 2000, pp. 1341-6.
|
|
Salameh G, Karamsetty MR, Warburton RR, Klinger JR, Ou LC, Hill NS.
"Differences in acute hypoxic pulmonary vasoresponsiveness between rat strains: role of endothelium." Journal of Applied Physiology, vol. 87, no. 1, 1999, pp. 356-62.
|
|
Klinger JR, Warburton RR, Pietras LA, Smithies O, Swift R, Hill NS.
"Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice." The American journal of physiology, vol. 276, no. 5 Pt 1, 1999, pp. L868-74.
|
|
Klinger JR, Warburton RR, Pietras L, Hill NS.
"Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats." Journal of Applied Physiology, vol. 84, no. 5, 1998, pp. 1646-52.
|
|
Klinger JR, Siddiq FM, Swift RA, Jackson C, Pietras L, Warburton RR, Alia C, Hill NS.
"C-type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats." The American journal of physiology, vol. 275, no. 4 Pt 1, 1998, pp. L645-52.
|
|
Klinger JR, Warburton RR, Pietras LA, Swift R, John S, Hill NS.
"Exaggerated pulmonary hypertensive responses during chronic hypoxia in mice with gene-targeted reductions in atrial natriuretic peptide." Chest, vol. 114, no. 1 Suppl, 1998, pp. 79S-80S.
|
|
Klinger JR, Sanchez MP, Curtin LA, Durkin M, Matyas B.
"Multiple cases of life-threatening adenovirus pneumonia in a mental health care center." Am J Respir Crit Care Med, vol. 157, no. 2, 1998, pp. 645-9.
|
|
Greene JH, Klinger JR.
"The efficacy of inhaled nitric oxide in the treatment of acute respiratory distress syndrome. An evidence-based medicine approach." Critical Care Clinics, vol. 14, no. 3, 1998, pp. 387-409.
|
|
Muramatsu M, Tyler RC, Gutkowska J, Klinger JR, Hill NS, Rodman DM, McMurtry IF.
"Atrial natriuretic peptide accounts for increased cGMP in hypoxia-induced hypertensive rat lungs." The American journal of physiology, vol. 272, no. 6 Pt 1, 1997, pp. L1126-32.
|
|
Klinger JR, Wrenn DS, Warburton RR, Pietras L, Ou LC, Hill NS.
"Atrial natriuretic peptide expression in rats with different pulmonary hypertensive responses to hypoxia." The American journal of physiology, vol. 273, no. 1 Pt 2, 1997, pp. H411-7.
|
|
Colice GL, Hill N, Lee YJ, Du H, Klinger J, Leiter JC, Ou LC.
"Exaggerated pulmonary hypertension with monocrotaline in rats susceptible to chronic mountain sickness." Journal of Applied Physiology, vol. 83, no. 1, 1997, pp. 25-31.
|
|
Hill NS, Warburton RR, Pietras L, Klinger JR.
"Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats." Journal of Applied Physiology, vol. 83, no. 4, 1997, pp. 1209-15.
|
|
Klinger JR.
"Hemodynamics and positive end-expiratory pressure in critically ill patients." Critical Care Clinics, vol. 12, no. 4, 1996, pp. 841-64.
|
|
Klinger JR, Cutaia M.
"The natriuretic peptides. Clinical applications in patients with COPD." Chest, vol. 110, no. 5, 1996, pp. 1136-8.
|
|
Brem AS, Bina RB, Klinger JR, King T, Werner JC.
"Glucocorticoid metabolism in the newborn rat heart." Proceedings of the Society for Experimental Biology and Medicine, vol. 209, no. 2, 1995, pp. 146-51.
|
|
Hill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS.
"Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension." The American journal of physiology, vol. 266, no. 3 Pt 1, 1994, pp. L308-15.
|
|
Klinger JR, Arnal F, Warburton RR, Ou LC, Hill NS.
"Downregulation of pulmonary atrial natriuretic peptide receptors in rats exposed to chronic hypoxia." Journal of Applied Physiology, vol. 77, no. 3, 1994, pp. 1309-16.
|
|
Klinger JR, Petit RD, Curtin LA, Warburton RR, Wrenn DS, Steinhelper ME, Field LJ, Hill NS.
"Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP." Journal of Applied Physiology, vol. 75, no. 1, 1993, pp. 198-205.
|
|
Bunnett NW, Wu V, Sternini C, Klinger J, Shimomaya E, Payan D, Kobayashi R, Walsh JH.
"Distribution and abundance of neutral endopeptidase (EC 3.4.24.11) in the alimentary tract of the rat." The American journal of physiology, vol. 264, no. 3 Pt 1, 1993, pp. G497-508.
|
|
Klinger JR, Petit RD, Warburton RR, Wrenn DS, Arnal F, Hill NS.
"Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats." Journal of Applied Physiology, vol. 75, no. 4, 1993, pp. 1615-23.
|
|
Klinger JR, Moalli R, Warburton RR, Wrenn DS, Hill NS.
"C-receptor ligand blocks pulmonary clearance of atrial natriuretic peptide in isolated rat lungs." Proceedings of the Society for Experimental Biology and Medicine, vol. 201, no. 2, 1992, pp. 154-8.
|
|
Klinger JR, Bensadoun E, Corrao WM.
"Pulmonary complications from alveolar accumulation of carbonaceous material in a cocaine smoker." Chest, vol. 101, no. 4, 1992, pp. 1171-3.
|
|
Klinger JR, Hill NS.
"Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management." Chest, vol. 99, no. 3, 1991, pp. 715-23.
|
|
von Ardenne M, Klemm W, Klinger J.
"[Double-blind study on the long-lasting improvement of physical endurance following oxygen-multistep-therapy]." ZfA. Zeitschrift fur Alternsforschung, vol. 39, no. 1, 1984, pp. 17-30.
|
